Stifel Nicolaus Reaffirms "Hold" Rating for Sionna Therapeutics (NASDAQ:SION)

Key Points

• Stifel Nicolaus reaffirmed its “Hold” rating on Sionna Therapeutics and set a $7 price target, implying roughly 65% upside from the stock’s reported $4.24 price. Analysts overall maintain a “Moderate Buy” consensus with a $49.67 target.
• Sionna shares plunged 91.7% to $4.24 in heavy trading, near their 52-week low of $4.05. The company also reported a quarterly loss of $0.66 per share, missing estimates by $0.02.
• Insiders sold about 403,726 shares worth $18.3 million over the past 90 days, while major institutions including BlackRock, Vanguard and State Street increased or initiated positions.

Sionna Therapeutics (NASDAQ:SION - Get Free Report)'s stock had its "hold" rating reaffirmed by equities researchers at Stifel Nicolaus in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. They presently have a $7.00 price target on the stock. Stifel Nicolaus' price target would suggest a potential upside of 65.29% from the company's current price.

SION has been the topic of several other reports. Citizens Jmp reissued a "market outperform" rating and set a $63.00 price objective on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Freedom Capital downgraded Sionna Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 20th. BTIG Research restated a "buy" rating and set a $58.00 target price on shares of Sionna Therapeutics in a research report on Wednesday, May 13th. Wall Street Zen lowered Sionna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Finally, Wedbush started coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an "outperform" rating and a $53.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Sionna Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $49.67.

Sionna Therapeutics Trading Down 91.7%

NASDAQ:SION traded down $46.80 during midday trading on Monday, hitting $4.24. 13,002,311 shares of the company were exchanged, compared to its average volume of 468,554. Sionna Therapeutics has a fifty-two week low of $4.05 and a fifty-two week high of $54.97. The company has a market capitalization of $191.46 million, a PE ratio of -1.92 and a beta of 1.32. The company has a fifty day simple moving average of $42.35 and a 200 day simple moving average of $40.42.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, equities research analysts expect that Sionna Therapeutics will post -2.63 EPS for the current year.

Insider Activity

In other news, Director Orbimed Advisors Llc sold 85,918 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares in the company, valued at $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the firm's stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares of the company's stock, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 403,726 shares of company stock worth $18,259,354 in the last ninety days. Insiders own 5.10% of the company's stock.

Hedge Funds Weigh In On Sionna Therapeutics

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Sionna Therapeutics in the 2nd quarter valued at about $64,875,000. Eventide Asset Management LLC purchased a new stake in shares of Sionna Therapeutics during the fourth quarter worth about $26,290,000. Vanguard Group Inc. grew its holdings in shares of Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company's stock worth $33,620,000 after buying an additional 512,803 shares in the last quarter. State Street Corp raised its position in shares of Sionna Therapeutics by 188.7% in the fourth quarter. State Street Corp now owns 693,395 shares of the company's stock valued at $28,526,000 after buying an additional 453,196 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of Sionna Therapeutics by 30.1% in the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company's stock valued at $58,179,000 after buying an additional 335,942 shares during the last quarter.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source